Clinical Trial to Evaluate the Safety and Efficacy of "CITUS Dry Syrup" in Children With Perennial Allergic Rhinitis

Inclusion criteria

• Children aged over 24 months and under 15 years.
• Patients who was diagnosed with perennial allergic rhinitis by ImmunoCAP test.
• NIS mean total score of 1-week in baseline should be over 4.0.

Exclusion criteria

• Patient who is accompanied by the seriously abnormal symptom in respiratory system, such as pneumonia, cystic fibrosis, viral influenza, tuberculosis, asthma(status praesens).
• Patient who has cancer, diabetes mellitus, hypertension, CNS disease, and metabolic disease which need medication.
• Patient who has rhinitis not caused by allergy.
• Acute or chronic sinusitis.
• Patient who has medical history of allergy in seasonal pollen during the trial.
• Patient who has had eyes or nose surgery within 3 months prior to the trial.
• Patient who has had eye or upper airway infection within 1 week prior to the treatment period.
• Beginning immunotherapy or dose of change within 1 month prior to the trial.
• Patient who has clinical history of sensitivity to allergic rhinitis medication.
• Patient whose heart function is abnormal: including heart failure, abnormal ECG test value that is clinically significant.
• Patient who has experience to have participated in other clinical trial within 2 months prior to the trial.
• Patient who has taken contraindicated medications in this study within 1 week(baseline period) prior to the treatment period.
• For girl who had her first period, result of pregnancy test was positive.